MRC1 and metastatic prostate carcinoma: This case suggests that patients with progressive metastatic prostate cancer should receive genomic analysis of their tumor or cfDNA, and if coinciding HRR and MMR mutations co-exist, immunotherapy should be used first prior to PARP inhibition, as other mutations may be bystanders.